The fact that certain ethnic groups and specific populations residing in certain geographic areas carry an increased risk for @entity715 and that @entity715 occurs in young @entity1 without established risk factors indicates the presence of new, previously unrecognized inherited conditions predisposing to @entity715 . We are now aware that interindividual variations within the loci coding for proteins relevant to lipid and vascular metabolisms as well as @entity1003 are universally found. Platelets play central roles in @entity66 and @entity1187 , as demonstrated by histopathological findings and clinical observations showing the efficacy of antiplatelet therapies for these disorders. In this article, we show our recent findings on the association between @entity453 ( @entity453 ) and polymorphisms in platelet membrane glycoproteins. The glycoprotein (GP) Ib/IX complex is a receptor for @entity2880 factor, which mediates shear stress-dependent platelet activation. It has recently been implicated in the pathogenesis of @entity1187 . We have determined genotypes of the "size-polymorphism" of @entity27463 --i.e., the variable number (1-4) of a 13 @entity535 sequence (399-411)--in angiographically proven Japanese @entity453 @entity1 with @entity583 or @entity951 as well as in individuals from the general population with no history of @entity951 or other @entity299 and normal resting electrocardiograms (ECG). We have found that the genotypes having at least one 4-repeat allele (4R) are more frequently found in @entity1 than in controls. Logistic regression analyses for the adjustment of age, sex, and other acquired coronary risk factors provided an odds ratio of 7.94 (p=0.0043) for those with 4R vs. those without 4R, suggesting that the presence of 4R is an independent risk factor for @entity453 . The molecular mechanisms underlying this association are currently under investigation. Relationships between arterial @entity715 and polymorphisms in other platelet GPs (collagen receptor and fibrinogen receptor), @entity1003 factors, fibrinolytic factors, vasoactive substances, and factors relevant for lipid metabolisms are also discussed.

Genetic polymorphisms and risk of XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1187 :: ('MESH:D054058', 'Disease') :: ['acute coronary syndromes'] @entity66 :: ('MESH:D004194', 'Disease') :: ['cerebrovascular diseases'] @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction'] @entity535 :: ('CHEBI:33704', 'Chemical') :: ['amino acid'] @entity1003 :: ('MESH:D001778', 'Disease') :: ['blood coagulation'] @entity951 :: ('MESH:D000787', 'Disease') :: ['angina pectoris', 'angina'] @entity453 :: ('MESH:D003324', 'Disease') :: ['CAD', 'coronary artery disease'] @entity299 :: ('MESH:D006331', 'Disease') :: ['heart diseases'] @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombosis'] @entity27463 :: ('2811', 'Gene') :: ['GPIb alpha'] @entity2880 :: ('MESH:D014842', 'Disease') :: ['von Willebrand']
@entity453 :: (MESH:D003324,Disease) :: ['coronary artery disease']
